Novel targeted therapies for autoimmunity.
Novel targeted therapies for autoimmunity.
复制标题
自身免疫的新型靶向疗法。
DOI：
10.1016/j.coi.2009.09.008
复制
发表时间：
2009
影响因子：
7
通讯作者：
StClair,EWilliam
中科院分区：
文献类型：
--
作者：
StClair,EWilliam
新靶向治疗的出现正在迅速改善自身免疫性疾病的治疗。这些药物被设计用于消耗特定的T和B细胞亚群，中断受体-配体相互作用，并抑制与免疫功能相关的炎症介质的活性。阿巴西普（一种共刺激阻断剂）和利妥昔单抗（一种B细胞耗竭抗体）是寻求新适应症的获批疗法之一，而较新的疗法包括Fc受体非结合CD 3特异性抗体、IL-12/23抗体、IL-6受体拮抗剂、1-磷酸鞘氨醇激动剂和细胞内蛋白激酶的小分子抑制剂。抗原特异性治疗尚处于起步阶段，但谷氨酸脱氢酶肽治疗1型糖尿病的最新结果是有希望的。在未来，治疗策略可能会越来越多地探索使用药物组合作用于异常免疫调节的多个位点，以实现疾病静止和免疫耐受。
The emergence of new targeted therapies is rapidly improving the treatment of autoimmune disease. These drugs have been variably designed to deplete specific T and B cell subsets, interrupt receptor–ligand interactions, and inhibit the activity of inflammatory mediators relevant to immune function. Abatacept, a co-stimulatory blocker, and rituximab, a B cell depleting antibody, are among the approved therapies seeking new indications, while the newer therapies include Fc receptor-non-binding CD3-specific antibodies, IL-12/23 antibodies, an IL-6 receptor antagonist, a sphingosine-1-phosphate agonist, and small molecule inhibitors of intracellular protein kinases. Antigen-specific therapies are in their infancy, but the latest results administering glutamic acid dehydrogenase peptide to type 1 diabetics are promising. In the future, treatment strategies may increasingly explore the use of drug combinations acting at multiple sites of aberrant immunoregulation to achieve disease quiescence and immune tolerance.